AI Medical Coding & GLP-1 Microdosing News – STAT+
- Telehealth providers Noom, Found, and Hims & Hers have recently begun offering programs prescribing low-dose, or "microdosed," GLP-1 receptor agonists.
- The companies are promoting the idea that smaller doses of these drugs can provide a range of health benefits beyond weight management.
- Despite the marketing efforts,there is a lack of robust scientific data demonstrating the effectiveness of GLP-1 microdosing for any health benefit.
Telehealth Companies Market “Microdosing” of GLP-1 Drugs Despite Lack of Evidence
Expanding the Market for Popular Drugs
Telehealth providers Noom, Found, and Hims & Hers have recently begun offering programs prescribing low-dose, or “microdosed,” GLP-1 receptor agonists. These medications,originally developed to treat type 2 diabetes,have gained meaningful popularity for their weight loss effects.
The companies are promoting the idea that smaller doses of these drugs can provide a range of health benefits beyond weight management. However, current clinical evidence does not support these claims. This strategy represents a new effort to extend profitability from these in-demand medications.
Limited Clinical support for Microdosing
Despite the marketing efforts,there is a lack of robust scientific data demonstrating the effectiveness of GLP-1 microdosing for any health benefit. The practice relies on extrapolating from studies focused on standard, therapeutic doses used for diabetes and obesity treatment.
This approach raises concerns about whether patients are receiving genuine medical benefit or are simply paying for a placebo effect. It also highlights the potential for telehealth companies and their compounding pharmacy partners to capitalize on the demand for these drugs, even without strong evidence of efficacy.